SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 6, 2003
HALSEY DRUG CO., INC.
695 North Perryville Road, Rockford, Illinois 61107
(815-399-2060)
Incorporated under Commission File Number I.R.S. Employer
the laws of State of New York 1-10113 Identification Number
11-0853640
Item 5. Other Events
On November 6, 2003, Halsey Drug Co., Inc. (the "Company") issued a press
release disclosing its intention to restructure the Company's operations to
focus its efforts on research and development related to certain proprietary
finished dosage product. A copy of the Company's press release is attached as
Exhibit 99.1 hereto.
Item 7. Financial Statements and Exhibits.
(b) Exhibits
Exhibit
Number Description
------ -----------
99.1 Press Release of Halsey Drug Co., Inc. dated November 6, 2003.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
HALSEY DRUG CO., INC.
By: /s/ Peter A. Clemens
------------------------------------------
Peter A. Clemens
Vice President & Chief Financial Officer
Date: November 6, 2003
3
EXHIBIT INDEX
-------------
Exhibit
Number Description
------ ------------
99.1 Press Release of Halsey Drug Co., Inc. dated November 6, 2003.
4